Graypoint LLC Has $1.66 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Graypoint LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.0% during the third quarter, HoldingsChannel.com reports. The firm owned 5,164 shares of the medical research company’s stock after acquiring an additional 148 shares during the quarter. Graypoint LLC’s holdings in Amgen were worth $1,664,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Amgen by 5.3% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 64,427 shares of the medical research company’s stock worth $18,318,000 after acquiring an additional 3,246 shares during the period. AIA Group Ltd bought a new stake in shares of Amgen during the 1st quarter worth approximately $612,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Amgen by 33.0% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 7,498 shares of the medical research company’s stock worth $2,132,000 after acquiring an additional 1,860 shares during the period. Nelson Capital Management LLC lifted its holdings in shares of Amgen by 18.4% during the 1st quarter. Nelson Capital Management LLC now owns 18,654 shares of the medical research company’s stock worth $5,304,000 after acquiring an additional 2,901 shares during the period. Finally, Capital Wealth Planning LLC lifted its holdings in shares of Amgen by 28,684.1% during the 1st quarter. Capital Wealth Planning LLC now owns 833,300 shares of the medical research company’s stock worth $236,924,000 after acquiring an additional 830,405 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.0 %

AMGN opened at $321.91 on Friday. Amgen Inc. has a twelve month low of $260.52 and a twelve month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a fifty day moving average of $323.96 and a 200-day moving average of $316.68. The stock has a market cap of $173.04 billion, a PE ratio of 41.22, a price-to-earnings-growth ratio of 2.79 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same period in the prior year, the company posted $4.96 earnings per share. Amgen’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, sell-side analysts predict that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. Barclays increased their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Sanford C. Bernstein started coverage on shares of Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective for the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price objective (up previously from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $333.50.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.